Drug profile

The FDA adverse-event record for Glucosamine Chondroitin

48 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine Chondroitin. Species, reactions, and outcomes follow.

#1149 of 2,679
by report volume (all drugs)
48
adverse-event reports
27.1%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Glucosamine Chondroitin ranks #1140 of 2679 by total reports (48). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1140
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Glucosamine Chondroitin has 48 reports now versus 46 in that prior snapshot: 2 more (4.3%).

Report change
+2
Death-coded reports
+0
Death-coded share
−1.2 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Glucosamine Chondroitin changes

Signature read: Glucosamine Chondroitin's 27.1% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
48
Total Reports
13
Deaths Reported
27.1%
Death-coded share of reports

Active Ingredients

Glucosamine Chondroitin

Administration Routes

OralUnknown

Species Affected

Dog 42
Cat 6

Most Affected Breeds

Retriever - Labrador 8
Dog (unknown) 4
Retriever - Golden 4
Domestic Shorthair 4
Terrier - Bull - American Pit 3
Bulldog - French 3
Mastiff 2
Pointing Dog - Hungarian Short-haired (Vizsla) 2
Terrier (unspecified) 2
Shepherd Dog - German 2

Most Reported Reactions

Abnormal radiograph finding 11
Lethargy (see also Central nervous system depression in Neurological) 10
Death by euthanasia 8
Diarrhoea 7
Vomiting 6
Weight loss 6
Elevated alanine aminotransferase (ALT) 6
Inappropriate urination 6
Anorexia 5
Death 5
Other abnormal test result NOS 4
Elevated cholesterol (total) 4

Outcome Breakdown

Ongoing
21 (43.8%)
Euthanized
8 (16.7%)
Recovered/Normal
7 (14.6%)
Outcome Unknown
7 (14.6%)
Died
5 (10.4%)

Glucosamine Chondroitin: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Glucosamine Chondroitin (#1149 of 2,679 by report volume); death-coded 27.1%. PlainBreed drug row · death-coded share stamp 27.1% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →